Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 10 studies | 35% ± 11% |
Insufficient scRNA-seq data for expression of GPR17 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 94% | 1232.11 | 2490 / 2642 | 97% | 144.39 | 683 / 705 |
lung | 96% | 1046.16 | 554 / 578 | 16% | 0.45 | 183 / 1155 |
prostate | 87% | 664.56 | 214 / 245 | 24% | 0.48 | 119 / 502 |
breast | 95% | 902.77 | 437 / 459 | 12% | 0.32 | 133 / 1118 |
uterus | 97% | 1305.35 | 165 / 170 | 10% | 0.34 | 45 / 459 |
bladder | 95% | 987.43 | 20 / 21 | 10% | 0.26 | 52 / 504 |
esophagus | 76% | 1116.93 | 1094 / 1445 | 26% | 0.74 | 47 / 183 |
intestine | 85% | 1651.05 | 822 / 966 | 16% | 0.37 | 85 / 527 |
blood vessel | 98% | 1016.23 | 1312 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1258.58 | 843 / 861 | 0% | 0 | 0 / 0 |
adipose | 96% | 965.79 | 1151 / 1204 | 0% | 0 | 0 / 0 |
kidney | 58% | 292.39 | 52 / 89 | 36% | 1.12 | 320 / 901 |
spleen | 94% | 820.17 | 226 / 241 | 0% | 0 | 0 / 0 |
thymus | 80% | 463.46 | 525 / 653 | 10% | 0.16 | 61 / 605 |
stomach | 62% | 572.63 | 222 / 359 | 17% | 0.39 | 50 / 286 |
ovary | 32% | 150.76 | 58 / 180 | 30% | 1.20 | 129 / 430 |
muscle | 56% | 213.89 | 451 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 20% | 68.35 | 52 / 258 | 32% | 1.81 | 74 / 230 |
skin | 36% | 148.62 | 649 / 1809 | 14% | 3.36 | 67 / 472 |
pancreas | 9% | 26.86 | 28 / 328 | 35% | 0.83 | 63 / 178 |
liver | 23% | 76.44 | 52 / 226 | 17% | 0.46 | 67 / 406 |
eye | 0% | 0 | 0 / 0 | 9% | 0.23 | 7 / 80 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.07 | 1 / 29 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
peripheral blood | 0% | 0.43 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0070098 | Biological process | chemokine-mediated signaling pathway |
GO_0035025 | Biological process | positive regulation of Rho protein signal transduction |
GO_0002862 | Biological process | negative regulation of inflammatory response to antigenic stimulus |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0048709 | Biological process | oligodendrocyte differentiation |
GO_0005886 | Cellular component | plasma membrane |
GO_0004950 | Molecular function | chemokine receptor activity |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0033612 | Molecular function | receptor serine/threonine kinase binding |
Gene name | GPR17 |
Protein name | Uracil nucleotide/cysteinyl leukotriene receptor (UDP/CysLT receptor) (G-protein coupled receptor 17) (P2Y-like receptor) (R12) G protein-coupled receptor 17 isoform b G protein-coupled receptor 17 |
Synonyms | |
Description | FUNCTION: Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia. . |
Accessions | ENST00000272644.7 [Q13304-1] ENST00000423019.1 ENST00000393018.3 [Q13304-1] G4XH68 Q13304 ENST00000486700.2 [Q13304-2] C9JWY5 ENST00000544369.5 [Q13304-1] |